Overview

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel